This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Acura Pharmaceuticals, Inc.
Drug Names(s): oxycodone HCl + acetaminophen, oxycodone HCl + paracetamol, oxycodone HCl + APAP
Description: Acuracet is an immediate release opioid analgesic tablet and is designed to introduce limits and impediments to potential abuse via nasal snorting of crushed tablets and intravenous injection of dissolved tablets.
Acura and King
In October 2007, King Pharmaceuticals and Acura Pharmaceuticals announced that the companies have entered into a License, Development and Commercialization Agreement (the Agreement) for the United States, Canada, and Mexico (the Territory) encompassing a potentially wide range of opioid analgesic products utilizing Acura's patented Aversion Technology platform. The companies have initially targeted development and commercialization of four immediate release opioid analgesic products, including ACUROX Tablets.
Pfizer and King
In October 2010, Pfizer and King Pharmaceuticals announced that they have entered into a definitive merger agreement. In February 2011, Pfizer completed its acquisition of King.
Acura and PfizerIn July 2012, Acura announced that Pfizer provided notice that it is exercising its right to terminate the license to three development stage products using Acura's AVERSION Technology and return such products to Acura....See full deal structure in Biomedtracker
Additional information available to subscribers only: